Therapeutic Effective Of Atorvastatin In The Treatment Of Cerebral Infarction By Exploring The Non-lipid Modulation

Objective:To demonstrate the therapeutic effect of atorvastatin a in the treatment of cerebral infarction patients by exploring the non-lipid modulation of atorvastatin.Methods:70 patients with cerebral infarction were randomly divided into observation group (atorvastatin treatment group) and control group (routine treatment), each group has 35 cases, control group was uesd conventional treatment, observation group was gaved atorvastatin based on the control group, six months in a row, and detected the c-reactive protein (CRP), bilateral carotid ultrasound, to half a year of follow-up, patients with America’s national institutes of health stroke scale (NIHSS) scores and daily life function scale (ADL) score before and after treatment 1 month,3 months after treatment.observed blood rheology indexes (rate of platelet aggregation, fibrinogen, prothrombin time) of two groups, and checked P38MAPK, MIR21D expression level of two groups, scored the life qility of two groups with the U.S. national institutes of health stroke scale (NIHSS) scores and daily life function scale (ADL) score, compared the treatment effect of the two groups with the statistical analysis results.Results:Basic in observation group,10 cases were cured,13 cases of remarkable progress, progress in 7 cases,4 cases were invalid, deterioration in 1 case, the total effective rate was 85.7%(30/35). Control basic recovery in 8 cases,12 cases remarkable progress, progress in 5 cases,8 no effect, the deterioration in 2 cases, the total effective rate was 71.4% (25/35). Compared two groups, observation group total effective rate was higher than the control group, compared with significant differences (P< 0.05). Two groups of patients after a course of treatment, life ability, compared with before treatment, life ability index compared before treatment in both groups were significantly increased, with statistical significance (P< 0.05). Observation group ascension efficient is higher than the control group, with statistical significance (P< 0.05). Observation group of patients after 3 months after treatment TNF alpha, CRP, IL-6 are lower than before the treatment, IMT is less than before the treatment, was statistically significant (P< 0.05). Observation group of patients after 3 months after treatment TNF alpha, CRP, IL-6, are less than 3 months after treatment, IMT is less than 3 months after treatment, with statistical significance (P < 0.05). Observation group 3 months after treatment the NIHSS score lower than before the treatment, was statistically significant (P< 0.05). Observation group 6 months after treatment the NIHSS score lower than 3 months after treatment, with statistical significance (P< 0.05). Found that three months after treatment group patients before P38MAPK, MIR21D mRNA expression level and treatment had significant difference (P< 0.05), found that six months observation group of patients after treatment of P38MAPK, MIR21D mRNA expression level and the level of three months after treatment there are significant differences (P< 0.05).Conclusion:atorvastatin could be reduce the inflammatory factor levels significantly, and could be give play to the role of the improving the neural function and life ability, so is worth promoting.